Classic CHA₂DS₂-VASc Score Calculator
Calculate the classic 2010 CHA₂DS₂-VASc risk-factor point total for adults with clinician-established atrial fibrillation or atrial flutter.
Content updated: View sources
QuickMedCalc is developed and maintained by an independent developer. Medical content is not independently reviewed by a physician.
Formula and medical content are based on the references listed on this page. See sources, About, and Sources and Review Process.
Before calculating: select the adult AF/flutter context only when it has been clinically established, then enter every classic-model response. This page does not screen for AF, read an ECG, or make a treatment decision.
About
This page reproduces the classic 2010 CHA₂DS₂-VASc point score for an adult whose atrial fibrillation or atrial flutter has already been established by an appropriate clinical evaluation. The original publication describes a risk-factor approach for stroke and systemic thromboembolism in AF; this is not an AF diagnosis, screening, ECG-reading, or symptom-assessment tool. [1]
Olesen and Friberg validated score behaviour in large AF cohorts, but their populations, outcomes, anticoagulant exposure, follow-up, and study methods were not identical. A higher score can track higher event rates at the population level without yielding one universal annual percentage for every person. [2, 3]
The original binary female-sex point is retained solely because this calculator reproduces the classic arithmetic. Later evidence describes female sex as a risk modifier that interacts with other factors rather than an isolated treatment trigger. It does not represent gender identity, chromosomes, hormone status, or a coefficient inferred by this site. [4]
The 2023 U.S. guideline uses validated risk tools and annual thromboembolic-risk estimation, while the 2024 ESC guideline uses the sex-neutral CHA₂DS₂-VA pathway. Those guideline systems are shown separately below; this page calculates neither an individual annual risk nor an automatic treatment plan. [5, 6]
Formula
Interpretation
Classic runtime components and current ESC comparison
| Letter | Classic runtime meaning | Points | Important boundary | 2024 ESC comparison |
|---|---|---|---|---|
| C | Congestive heart failure / LV dysfunction | 1 | Clinically established qualifying history; this page does not infer it from symptoms. | The ESC pathway also defines its heart-failure item separately; do not rewrite the classic input. |
| H | Hypertension | 1 | Clinically documented hypertension or applicable treatment under the source pathway. | The current ESC definition is part of CHA₂DS₂-VA and is not silently substituted here. |
| A₂ | Age ≥75 years | 2 | Mutually exclusive with the 65–74 band. | Age remains a component in CHA₂DS₂-VA, with the current pathway’s own definitions. |
| D | Diabetes mellitus | 1 | Clinically established diabetes; no inference from one unconfirmed reading. | The ESC pathway has its own diabetes definition. |
| S₂ | Prior stroke, TIA, or systemic thromboembolism | 2 | One doubled history item; TIA and systemic embolism require clinical documentation. | The ESC pathway retains prior stroke or systemic embolism in its own score. |
| V | Vascular disease | 1 | Classic examples: prior myocardial infarction, peripheral artery disease, or aortic plaque. | 2024 ESC gives more detailed CAD/PVD definitions; those details do not alter this classic runtime. |
| A | Age 65–74 years | 1 | Mutually exclusive with age ≥75; age <65 contributes 0. | Age bands belong to the separate CHA₂DS₂-VA pathway as well. |
| Sc | Female sex category in the original binary model | 1 | Kept only to reproduce the classic 2010 arithmetic; not a stand-alone treatment trigger. | ESC CHA₂DS₂-VA omits sex. This page does not calculate or convert to it. |
The classic 2010 table is the only model executed by this page. The 2024 ESC CHA₂DS₂-VA comparison is static context; it removes the sex item and uses its own current definitions for vascular and other domains. [1, 6]
Two current guideline frames, kept separate
| Framework | Static context | What this calculator does not do |
|---|---|---|
| 2023 U.S. guideline | Uses validated clinical risk tools, annual thromboembolic-risk estimation, additional modifiers, and shared decision-making. CHA₂DS₂-VASc is one option, and the same score can have very different absolute risks across cohorts. [5] | It does not estimate a personal annual percentage or select treatment. |
| 2024 ESC guideline | Uses CHA₂DS₂-VA without the sex category, with its own thresholds and pathway. [6] | It is not silently merged with the classic score calculated here. |
Because cohort event rates vary by population, outcome definition, anticoagulant exposure, follow-up, and study design, this page does not publish a score-to-percentage lookup table. [2, 3, 5]
What this page can and cannot observe
Use this form only after adult AF or atrial flutter has been clinically established. It does not read an ECG, watch, pulse, or symptoms; it cannot detect, screen for, diagnose, or exclude an arrhythmia. It also does not measure bleeding risk, calculate HAS-BLED, estimate an individual annual stroke probability, or select anticoagulation.
The female-sex category is a historical model component
The classic model assigns one point to the original binary female sex category, so the runtime keeps it and can produce a female-only score of 1. Current evidence treats sex as a modifier that interacts with other stroke-risk factors, not an isolated automatic treatment trigger. The 2024 ESC pathway removes it in CHA₂DS₂-VA. This page does not infer gender identity, hormone status, chromosomes, or an alternative coefficient, and does not calculate the ESC score. [4, 6]
Why a fixed annual percentage is not shown
Olesen and Friberg reported useful population-level validation, but the cohorts differed in anticoagulation exposure, outcome ascertainment, and follow-up. The 2023 U.S. guideline likewise cautions that absolute annual risk at a given score varies widely between populations. A submitted score is therefore a point total at one time, not a universal individual prognosis. [2, 3, 5]
Special pathways are not hidden score branches
Moderate-to-severe rheumatic mitral stenosis, a mechanical heart valve, hypertrophic cardiomyopathy, device-detected atrial high-rate episodes or subclinical AF, recent cardioversion or ablation, pregnancy, congenital heart disease, and recent stroke or intracranial haemorrhage may require separate timing, definitions, or treatment pathways. This page does not decide whether a special pathway applies and does not give a medicine, dose, monitoring target, or duration. [5, 6]
CHA₂DS₂-VASc and HAS-BLED answer different questions
CHA₂DS₂-VASc groups thromboembolic risk factors in established AF or flutter; HAS-BLED reviews bleeding-risk factors. They cannot be subtracted, and a bleeding score is not a treatment contraindication or a net-clinical-benefit calculation. Visit the HAS-BLED calculator for that separate arithmetic question.
Reassessment is a clinical process
Age, heart failure, hypertension, diabetes, prior stroke or thromboembolism, and vascular disease can change over time. A future submission may therefore produce a different point total, but that change is not a treatment effect or a recommendation. The applicable clinical team determines when and how to reassess. [2, 5]
References
- Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263–272. PMID 19762550. DOI 10.1378/chest.09-1584.
- Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. PMID 21282258. DOI 10.1136/bmj.d124.
- Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500–1510. PMID 22246443. DOI 10.1093/eurheartj/ehr488.
- Nielsen PB, Skjøth F, Overvad TF, Larsen TB, Lip GYH. Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation. Circulation. 2018;137(8):832–840. PMID 29459469. DOI 10.1161/CIRCULATIONAHA.117.029081.
- Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149(1):e1–e156. PMID 38033089. PMCID PMC11104284. DOI 10.1161/CIR.0000000000001193. The current online version incorporates corrections 10.1161/CIR.0000000000001207, 10.1161/CIR.0000000000001218, and 10.1161/CIR.0000000000001263.
- Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2024;45(36):3314–3414. PMID 39210723. DOI 10.1093/eurheartj/ehae176.
FAQ
It reproduces the classic 2010 risk-factor point score: congestive heart failure or left-ventricular dysfunction (1), hypertension (1), age 65–74 (1) or age at least 75 (2), diabetes (1), prior stroke, transient ischemic attack or systemic thromboembolism (2), vascular disease (1), and female sex category in the original binary model (1). The total range is 0–9.
Sources: [1]
AF means atrial fibrillation. TIA means transient ischemic attack. Systemic thromboembolism means an embolic event outside the brain, such as an acute arterial embolus to a limb or organ; these histories must be clinically established rather than inferred by this calculator.
Sources: [1]
No. Age is entered once and contributes one mutually exclusive band: younger than 65 years adds 0, 65–74 adds 1, and 75 or older adds 2. The one-point and two-point age categories must never be added together.
Sources: [1]
No. Published event rates at the same point total vary across cohorts because populations, outcome definitions, anticoagulant exposure, follow-up, and study methods differ. The 2023 U.S. guideline also emphasizes absolute annual risk and additional modifiers rather than treating one table as a universal individual prediction.
A point total is only one input to an applicable contemporary pathway. Treatment decisions can depend on estimated absolute risk, bleeding considerations, valve disease, AF context, comorbidities, contraindications, patient preferences, and the specific guideline in use. This educational calculator does not choose a medicine, dose, duration, or monitoring plan.
No. Classic CHA₂DS₂-VASc groups stroke and systemic-thromboembolism risk factors in established AF or flutter. HAS-BLED addresses bleeding-risk factors in a different context. The two totals must not be subtracted from each other or treated as competing arithmetic.
Sources: [5]
Related Calculators
HAS-BLED
Calculate the original 2010 HAS-BLED 0–9 bleeding-risk-factor score for adults with established atrial fibrillation.
Framingham
Calculate the D’Agostino 2008 lipid-based 10-year Framingham general CVD estimate for eligible adults aged 30–74 without established cardiovascular disease.
ASCVD
Estimate 10-year and age-eligible 30-year risk of a first ASCVD event with the corrected AHA PREVENT base equations.
Disclaimer
Educational and informational reference only. Not intended to replace professional medical advice, diagnosis, treatment, or independent verification.